# US 2026/0306488 A1 · Functional protective agent for organ or tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306488 A1
- Document ID: US20260306488A1
- Status: Published application
- Kind: A1
- Application number: 19/484,943
- Filed: 2024-05-24
- Published: 2026-10-08
- Earliest claimed: 2023-05-26
- Assignees: Tohoku University; Jellice Co., Ltd.
- Applicants: Tohoku University; JELLICE Co., Ltd.
- Inventors: Takaaki Abe; Koichi Kikuchi; Toru Nakayama; Daiki Oikawa; Noriaki Numata; Shoko Yamamoto; Yo Matsumoto; Fumihiro Yambe
- Web page: https://patentgrep.com/patent/US20260306488A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide a low-molecular-weight compound that is highly safe when ingested, and has an effect of preventing or improving dysfunction of an organ or a tissue. One or more compounds selected from a compound of the following formula (I), and a physiologically acceptable salt thereof are used as an agent for preventing or improving dysfunction of an organ or a tissue: [wherein R1 and R2 each independently represent H or a C1-C6 alkyl group, R3 and R4 each independently represent H; or a C1-C6 alkyl group optionally having at least one group selected from the group consisting of a hydroxy group, a phenyl group, a hydroxyphenyl group, a S—CH3 group, a NH2 group, a carboxy group, a carbamoyl group, a guanidino group, and a N-containing heteroaryl group, R1 and R3 optionally form a ring via a C2-C4 alkylene group optionally having a hydroxy group, and R2 and R4 optionally form a ring via a C2-C4 alkylene group optionally having a hydroxy group.]

## Claims

### Claim 1

A method for preventing or improving dysfunction of an organ or a tissue, comprising making a mammal in need of prevention or improvement of dysfunction of an organ or a tissue ingest one or more compounds selected from the group consisting of a compound of the following formula (I), and a physiologically acceptable salt thereof:
[wherein
R1 and R2 each independently represent H or a C1-C6 alkyl group,
R3 and R4 each independently represent H; or a C1-C6 alkyl group optionally having at least one group selected from the group consisting of a hydroxy group, a phenyl group, a hydroxyphenyl group, a S—CH3 group, a NH2 group, a carboxy group, a carbamoyl group, a guanidino group, and a N-containing heteroaryl group,
R1 and R3 optionally form a ring via a C2-C4 alkylene group optionally having a hydroxy group, and
R2 and R4 optionally form a ring via a C2-C4 alkylene group optionally having a hydroxy group.]

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is a compound of the following formula (I-1):

### Claim 3 (depends on 1)

The agent-method according to claim 1, wherein the organ is kidney or liver.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the mammal is a mammal suffering from renal failure or diabetes.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the organ kidney or liver.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the mammal is a mammal suffering from renal failure or diabetes.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the mammal is a mammal suffering from renal failure or diabetes.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the mammal is a mammal suffering from renal failure or diabetes.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 11 (depends on 3)

The method according to claim 3, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 12 (depends on 4)

The method according to claim 4, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 13 (depends on 6)

The method according to claim 6, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 14 (depends on 7)

The method according to claim 7, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.

### Claim 16 (depends on 9)

The method according to claim 9, wherein the compound is used as a pharmaceutical, a pet food, or a food/drink product.
